NASDAQ:CRVS

Corvus Pharmaceuticals Stock Predictions

etoro logo Buy CRVS
*Your capital is at risk
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

CRVS Prediction Chart

CRVS Predictions History

Latest community submissions for CRVS.
Predictor Target Session Target Price Result Direction Accuracy Score
Feb 25, 2026 $17.23 -3.31% $18.20 X 94.68% 0
Feb 25, 2026 $18.19 +2.07% $18.20 V 99.93% 10
Feb 25, 2026 $18.18 +2.02% $18.20 V 99.89% 6
Oct 16, 2024 $6.54 -2.74% $7.35 X 88.93% 0
Oct 16, 2024 $6.61 -1.71% $7.35 X 89.87% 0
Oct 16, 2024 Bullish $7.35 V 1
Oct 14, 2024 $6.15 -2.77% $6.79 X 90.65% 0
Oct 14, 2024 $6.22 -1.73% $6.79 X 91.61% 0
Oct 14, 2024 $6.45 +1.90% $6.79 V 94.99% 1
JS JS Pro
Aug 16, 2022 $1.14 +0.88% $1.08 X 94.44% 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CRVS with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE